Dataset Information

Immunohistochemical study of N-epsilon-carboxymethyl lysine (CML) in human brain: relation to vascular dementia.

ABSTRACT:

Background

Advanced glycation end-products (AGEs) and their receptor (RAGE) occur in dementia of the Alzheimer's type and diabetic microvascular disease. Accumulation of AGEs relates to risk factors for vascular dementia with ageing, including hypertension and diabetes. Cognitive dysfunction in vascular dementia may relate to microvascular disease resembling that in diabetes. We tested if, among people with cerebrovascular disease, (1) those with dementia have higher levels of neuronal and vascular AGEs and (2) if cognitive dysfunction depends on neuronal and/or vascular AGE levels.

Methods

Brain Sections from 25 cases of the OPTIMA (Oxford Project to Investigate Memory and Ageing) cohort, with varying degrees of cerebrovascular pathology and cognitive dysfunction (but only minimal Alzheimer type pathology) were immunostained for Nepsilon-(carboxymethyl)-lysine (CML), the most abundant AGE. The level of staining in vessels and neurons in the cortex, white matter and basal ganglia was compared to neuropsychological and other clinical measures.

Results

The probability of cortical neurons staining positive for CML was higher in cases with worse cognition (p = 0.01) or a history of hypertension (p = 0.028). Additionally, vascular CML staining related to cognitive impairment (p = 0.02) and a history of diabetes (p = 0.007). Neuronal CML staining in the basal ganglia related to a history of hypertension (p = 0.002).

Conclusion

CML staining in cortical neurons and cerebral vessels is related to the severity of cognitive impairment in people with cerebrovascular disease and only minimal Alzheimer pathology. These findings support the possibility that cerebral accumulation of AGEs may contribute to dementia in people with cerebrovascular disease.

SUBMITTER: Southern L

PROVIDER: S-EPMC2100062 | biostudies-literature | 2007 Oct

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Immunohistochemical study of N-epsilon-carboxymethyl lysine (CML) in human brain: relation to vascular dementia.

Southern Louise L Williams Jonathan J Esiri Margaret M MM

BMC neurology 20071016

<h4>Background</h4>Advanced glycation end-products (AGEs) and their receptor (RAGE) occur in dementia of the Alzheimer's type and diabetic microvascular disease. Accumulation of AGEs relates to risk factors for vascular dementia with ageing, including hypertension and diabetes. Cognitive dysfunction in vascular dementia may relate to microvascular disease resembling that in diabetes. We tested if, among people with cerebrovascular disease, (1) those with dementia have higher levels of neuronal a ...[more]

PMID: 17939855

Similar Datasets

Project description:Abstract Objectives Dietary advanced glycation end products (AGEs) are a group of compounds formed by the Maillard reaction. Carboxymethyl-lysine (CML), a marker of AGEs in foods, may contribute to cardiometabolic diseases. However, CML health effects and its absorption and excretion in healthy individuals remained controversial. For this reason, the aim of this study was to evaluate serum and urinary excretion CML levels in healthy adults after a short-term diet high in CML. Methods A randomized clinical trial was conducted in 30 healthy adults (18–35 years old). After signing the informed consent, subjects were randomly assigned to a low or a high CML diet. All participant followed a diet with low CML content for seven days (washing period) before the 5-days intervention. During the 5 days participants received all the foods according to their group. Blood and 24-hour urine samples were collected before and after the intervention to evaluate serum and urinary CML levels. CML measurement in foods, serum, and urine was carried out by HPLC-ESI-ITMS/MS. Comparison between groups was carried out by a t-test. The research was approved by the Institutional Review Board and the clinical trial registration number NCT03208946. Results Biochemical and anthropometric variables were similar between groups (P > 0.05). The average consumption of CML was 1.93 ± 1.47 mg/day for the low CML diet and 5.03 ± 2.22 mg/day for the high CML diet, whereas caloric, protein and fat intake were similar. Serum levels decreased significantly in both groups (low diet: basal 488.1 ± 135.4 μg/L, final 383.2 ± 78.6 μg/L (P = 0.007)) (high diet: basal 463.5 ± 90.3 μg/L, final 390.3 ± 99.1 μg/L (P = 0.02)). No significant difference was found when comparing the final CML levels between groups (P = 0.47). The excretion of CML in urine was adjusted by creatinine (mg) and the high CML group had a greater excretion (4.5 ± 8.0 ug CML/mg) when compared to the low CML group (−1.5 ± 7.2 ug CML/mg) (P = 0.04). Conclusions A high CML diet increases urinary CML excretion levels in healthy adults when compared to a low CML diet. There were no significant differences in serum CML levels between both groups. However, a greater decrease was observed in the subjects who followed a diet with a low content of AGEs. Funding Sources University of Guanajuato. CONACYT.

Dataset Information

Immunohistochemical study of N-epsilon-carboxymethyl lysine (CML) in human brain: relation to vascular dementia.

Background

Methods

Results

Conclusion

Publications

Immunohistochemical study of N-epsilon-carboxymethyl lysine (CML) in human brain: relation to vascular dementia.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets